Verastem, Inc. Repayments of Long-Term Debt
Verastem, Inc. (VSTM) reported Repayments of Long-Term Debt of $42.58 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-06
- Verastem, Inc. repayments of long-term debt for the quarter ending 2025-12-31 was -$1.00K.
- Verastem, Inc. repayments of long-term debt for the quarter ending 2025-09-30 was $0.00.
- Verastem, Inc. repayments of long-term debt for the quarter ending 2025-06-30 was $0.00.
- Verastem, Inc. repayments of long-term debt for the quarter ending 2025-03-31 was $42.58M.
- Verastem, Inc. repayments of long-term debt for fiscal 2025 was $42.58M.
- Verastem, Inc. repayments of long-term debt for fiscal 2023 was $300.00K.
- Verastem, Inc. repayments of long-term debt for fiscal 2020 was $37.37M, a 206.93% increase from fiscal 2019.
- Verastem, Inc. repayments of long-term debt for fiscal 2019 was $12.17M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$1.00K derived: sum of 2 quarters · filed 2026-03-04 | -$1.00K derived: sum of 3 quarters · filed 2026-08-06 | $42.58M 10-K · filed 2026-03-04 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $42.58M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $42.58M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $42.58M 10-Q · filed 2026-05-07 | |||
| 2023-12-31 | $300.00K 10-K · filed 2025-03-20 | |||
| 2020-12-31 | $37.37M 10-K · filed 2023-03-14 | |||
| 2019-12-31 | $12.17M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |